Graphene oxide as a potential drug delivery system: evaluation of biocompatibility in vivo
- Медицина / Наукові статті / Англійською
- Тетяна Ігорівна ДУМИЧ/Tetiana DUMYCH/Соломія Ярославівна ПАРИЖАК/Solomiya PARYZHAK/Nadia SKOROKHYD/Svitlana PRYLUTSKA/Uwe RITTER/Yuriy PRYLUTSKYY/Rostyslav PANCHUK
-
Співавтори:
-
Науковий керівник / консультант:
-
Голова СВР:
-
Опоненти:
-
Рецензенти:
-
Кафедра:
кафедра гістології цитології та ембріології ДНТ «Львівський національний медичний університет імені Короля Данила»/Department of Histology Cytology and Embryology of SNPC "King Danylo Lviv National Medical University"/кафедра медичної біології паразитології та генетики ДНТ «Львівський національний медичний університет імені Короля Данила»/Department of Medical Biology Parasitology and Genetics of SNPC "King Danylo Lviv National Medical University" -
НДР:
-
УДК:
-
Doi:
https://doi.org/10.1080/1061186X.2026.2737801 -
ISBN:
- 6
Abstract
Graphene oxide (GO) has considerable potential as a highly efficient nanocarrier for drug delivery, but many toxicity studies have been limited to a single intravenous injection, which does not provide a complete picture of its biocompatibility in vivo. This study investigates the long-term, dose-related safety profile and systemic inflammatory responses to submicron-sized GO under a repeated-dose regimen relevant to drug-delivery applications. BALB/c mice received repeated intraperitoneal injections of unmodified GO sheets at cumulative doses of 10 mg/kg or 25 mg/kg, with longitudinal monitoring up to 60 days. The 10 mg/kg dose of GO was well tolerated, with no adverse changes in hematological parameters or biochemical markers of hepatic and renal function. In contrast, the 25 mg/kg cumulative dose was associated with a low-grade systemic inflammatory response, characterised primarily by increased circulating neutrophils. Serum biochemistry revealed a non-significant trend towards elevated aspartate aminotransferase activity, while creatinine levels remained unchanged. Overall, our findings delineate dose-related safety considerations for GO-based drug delivery design, validating the lower cumulative dose of 10 mg/kg as well tolerated. The intraperitoneal administration model may also provide a useful alternative for evaluating the systemic effects of GO while avoiding direct intravenous exposure.
Keywords: Graphene oxide, nanocarrier, in vivo, cumulative dose, biocompatibility
Коментарів 0